<DOC>
	<DOCNO>NCT00633373</DOCNO>
	<brief_summary>Currently approve therapy lung transplant recipient United States ( US ) . Treatment CIS follow lung transplantation previously demonstrate result clinically meaningful improvement survival chronic rejection-free survival compare placebo , additional data support use need prior Food Drug Administration ( FDA ) approval . This treatment use protocol mechanism provide eligible lung transplant recipient early access CIS advance FDA approval .</brief_summary>
	<brief_title>Cyclosporine Inhalation Solution ( CIS ) Lung Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Singleor doublelung transplant recipient high risk develop chronic rejection Single doublelung transplant recipient develop chronic rejection Single doublelung transplant recipient serious lifethreatening complication systemic immunosuppressive therapy Known hypersensitivity cyclosporine propylene glycol ( PG ) Females pregnant consider become pregnant Females breast feeding child .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>lung</keyword>
	<keyword>transplant</keyword>
	<keyword>transplant rejection</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>bronchiolitis obliterans</keyword>
	<keyword>aerosol</keyword>
</DOC>